首页> 外文期刊>Journal of experimental & clinical cancer research : >miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST
【24h】

miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST

机译:miR-33a在化学耐药性骨肉瘤中上调,并通过下调TWIST促进骨肉瘤细胞对顺铂的耐药性

获取原文
           

摘要

Background miRNAs are involved in osteosarcoma (OS) chemoresistance, and TWIST reportedly enhances cisplatin-induced OS cell apoptosis by inhibiting multiple signaling pathways. In this study, we profiled miRNAs differentially expressed in chemoresistant OS, with a focus to identify miRNAs that regulate TWIST expression and OS chemoresistance. Methods OS patients who showed Results Among the up-regulated miRNAs in chemoresistant OS samples, miR-33a was verified to down-regulate TWIST expression, which was supported by an inverse miRNA-33a/TWIST expression trend in the validation cohort (n?=?70), target-sequence-specific inhibition of TWIST-3′ untranslated region-luciferase reporter activity by miR-33a, and alteration of TWIST expression by overexpression or inhibition of miR-33a in human OS cell lines. In Saos-2 cells treated with cisplatin, inhibition of miR-33a by antagomir-33a markedly increased cell apoptosis, which was enhanced by overexpression of TWIST. The apoptosis-inducing effect of TWIST overexpression was reversed by overexpression of miR-33a. In MG-63 cells, overexpression of miR-33a significantly decreased cisplatin-induced cell apoptosis, which was enhanced by knockdown of TWIST. Antagomir-33a significantly increased cisplatin-induced cell apoptosis, which was reversed by knockdown of TWIST. Conclusions We have demonstrated in this study that miR-33a is up-regulated in chemoresistant OS and that the miR-33a level is negatively correlated with the TWIST protein level in OS. Our in vitro data indicate that miR-33a promotes OS cell resistance to cisplatin by down-regulating TWIST; on the other hand, inhibition of miR-33a by antagomir-33a enhances cisplatin-induced apoptosis in OS cells by up-regulating TWIST expression. The findings suggest that inhibition of miR-33a/TWIST signaling could be a potential new strategy to enhance neoadjuvant chemotherapy for OS.
机译:背景miRNA参与骨肉瘤(OS)的化学抗药性,据报道TWIST通过抑制多种信号通路增强顺铂诱导的OS细胞凋亡。在这项研究中,我们分析了在化学抗性OS中差异表达的miRNA,重点是鉴定调节TWIST表达和OS化学抗性的miRNA。方法显示结果的OS患者在耐药性OS样品中上调的miRNA中,证实miR-33a下调TWIST表达,这在验证队列中得到了miRNA-33a / TWIST逆表达趋势的支持(n = 70),靶序列特异性抑制miR-33a对TWIST-3'非翻译区荧光素酶报道分子的活性,以及​​通过在人OS细胞系中过表达或抑制miR-33a改变TWIST的表达。在用顺铂处理的Saos-2细胞中,antagomir-33a对miR-33a的抑制作用明显增加了细胞凋亡,而TWIST的过表达增强了它的凋亡。 miR-33a的过表达逆转了TWIST过表达的凋亡诱导作用。在MG-63细胞中,miR-33a的过表达显着降低了顺铂诱导的细胞凋亡,而TWIST的抑制则增强了这种表达。 Antagomir-33a显着增加了顺铂诱导的细胞凋亡,这被TWIST的抑制逆转了。结论我们在这项研究中证明了miR-33a在耐化学性OS中被上调,而miR-33a水平与OS中的TWIST蛋白水平负相关。我们的体外数据表明,miR-33a通过下调TWIST促进OS细胞对顺铂的耐药性;另一方面,antagomir-33a对miR-33a的抑制作用可通过上调TWIST表达来增强顺铂诱导的OS细胞凋亡。研究结果表明,抑制miR-33a / TWIST信号可能是增强OS新辅助化疗的潜在新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号